Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) is a Nasdaq-listed operating company with a dual focus on biotechnology drug discovery and solar energy asset investments. The company, incorporated in Nevada with corporate operations in Neve Yarak, Israel, conducts its biotechnology activities through its wholly-owned subsidiary, MitoCareX Bio Ltd. MitoCareX Bio Ltd. is dedicated to redefining mitochondrial drug discovery, developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. A core component of their approach is the proprietary MITOLINE™ algorithm platform, which is an AI and data-driven computational biotech platform. This platform is designed for sequence analysis and alignment to prepare mitochondrial carrier proteins of the SLC25 family for 3D homology modeling, addressing the lack of solved three-dimensional structures for many human mitochondrial carriers. In addition to its biotechnology segment, Nexentis Technologies Inc. also invests in solar energy assets using a "Ready to Build" (RTB) business model, focusing on projects in Europe. The company also controls approximately 98% of Save Foods Ltd., an Israeli company specializing in post-harvest treatment technologies to reduce pathogen contamination in fruits and vegetables. Nexentis Technologies Inc. was formerly known as N2OFF, Inc. and rebranded in February 2026. Sources: [1] https://www.stocktitan.net/overview/NXTS/ [2] https://www.investing.com/equities/save-foods [3] https://marketchameleon.com/Overview/NXTS/Summary/ [4] https://www.home.saxo/en-sg/markets/stocks/nxts-xnas [5] https://www.kraken.com/stocks/nxts [6] https://intellectia.ai/news/monitor/nexentis-achieves-key-drug-discovery-milestone [7] https://www.nasdaq.com/press-release/n2off-announcing-corporate-rebranding-nexentis-technologies-innovative-ai-and-data [8] https://www.bitget.com/stock/nasdaq-nxts/what-is [9] https://seekingalpha.com/symbol/NXTS